
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular is well-positioned for future growth due to a strong financial position, with approximately $367 million in cash and marketable securities and strong operating cash flow. The company is focused on expanding its presence in the lucrative cardiac space and is pursuing external growth opportunities through acquisitions. Additionally, the company has demonstrated consistent double-digit organic top-line growth with material margin expansion and has a strong portfolio of products used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease.
Bears say
LeMaitre Vascular is seeing strong growth in its top and bottom line, with double-digit organic revenue growth, 350 bps expansion in gross margin, and a 41% increase in operating income. The company's focus on developing and marketing vascular devices for various surgical specialties has resulted in a diversified revenue stream. However, the increase in operating expenses and higher sales and marketing expense as a percentage of revenue may impact the company's profitability in the long term. Additionally, the company's debt of $169 million and continued investments in research and development may impact its cash flow.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares